T1	Participants 221 347	in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy
T2	Participants 370 417	Patients with measurable and assessable disease
T3	Participants 700 712	474 patients
T4	Participants 1082 1112	in platinum-sensitive patients
